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Background and the purpose of the study: Carvedilol nonselective β-adrenoreceptor blocker, chemically
(±)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxypHenoxy) ethyl] amino]-2-propanol, slightly soluble in ethyl ether; and
practically insoluble in water, gastric fluid (simulated, TS, pH 1.1), and intestinal fluid (simulated, TS without
pancreatin, pH 7.5) Compounds with aqueous solubility less than 1%W/V often represents dissolution rate limited
absorption. There is need to enhance the dissolution rate of carvedilol. The objective of our present investigation
was to compare chitosan and chitosan chlorhydrate based various approaches for enhancement of dissolution rate
of carvedilol.
Methods: The different formulations were prepared by different methods like solvent change approach to prepare
hydrosols, solvent evaporation technique to form solid dispersions and cogrind mixtures. The prepared formulations
were characterized in terms of saturation solubility, drug content, infrared spectroscopy (FTIR), differential scanning
calorimetry (DSC), powder X-ray diffraction (PXRD), electron microscopy, in vitro dissolution studies and stability
studies.
Results: The practical yield in case of hydrosols was ranged from 59.76 to 92.32%. The drug content was found to
uniform among the different batches of hydrosols, cogrind mixture and solid dispersions ranged from 98.24 to
99.89%. There was significant improvement in dissolution rate of carvedilol with chitosan chlorhdyrate as compare
to chitosan and explanation to this behavior was found in the differences in the wetting, solubilities and swelling
capacity of the chitosan and chitosan salts, chitosan chlorhydrate rapidly wet and dissolve upon its incorporation
into the dissolution medium, whereas the chitosan base, less water soluble, would take more time to dissolve.
Conclusion: This technique is scalable and valuable in manufacturing process in future for enhancement of
dissolution of poorly water soluble drugs.
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The rate of absorption and bioavailability of poorly water
soluble drugs is often controlled by the rate of dissolution
of the drug in gastrointestinal tract. Many technological
methods of enhancing the dissolution characteristics of
slightly water soluble drugs have been reported in litera-
ture. These include reducing particle size to increase the
surface area [1], solublization in surfactant system [2],* Correspondence: amol.shete@rediffmail.com
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provided the original work is properly cited.formation of water soluble complexes [3], use of prodrug,
drug derivatization and manipulation of solid state of drug
substance to improve drug dissolution i.e. by decreasing
drug crystallinity [4] or crystal engineering [5-7]. Chitosan
is a linear polycationic copolymer of b [1-4] linked
2-acetamido-2-deoxy-b-D-glucopyranose and 2- amino-
2-deoxy-b-D-glucopyranose obtained from deacetylation
of chitin, a structural polysaccharide which is very abun-
dantly distributed in nature [8]. In recent year’s chitosan
and chitosan derivatives has gained increasing interest in
the pharmaceutical field due to its favorable biological
properties such as biocompatibility, biodegradability, andicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
Table 1 Composition of carvedilol- chitosan and chitosan chlorhydrtate hydrosol formulations
Batch code Carvedilol (mg) Chitosan (%) Chitosan chlorhydrate (%) Glacial acetic acid (ml) Sodium citrate (2%w/v) (ml)
C1 500 0.05 - 20 100
C2 500 0.2 - 20 100
C3 500 0.4 - 20 100
C4 500 0.6 - 20 100
C5 500 1 - 20 100
C6 500 - 0.05 20 100
C7 500 - 0.2 20 100
C8 500 - 0.4 20 100
C9 500 - 0.6 20 100
C10 500 - 0.8 20 100
C11 500 - 1 20 100
C12 500 - - 20 100










C13 500 5 -
C14 500 20 -
C15 500 40 -
C16 500 60 -
C17 500 100 -
C18 500 - 5
C19 500 - 20
C20 500 - 40
C21 500 - 60
C22 500 - 80
C23 500 - 100
C24 500 - -
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and high versatility of use [9,10] Previously chitosan was
largely used as an excipient for oral drug solid dosage
forms, due to its binder, anti-adherent and disintegrant
properties [11-13].
Chitosan, being cationic polysaccharide in neutral or
basic pH conditions, contains free amino group and
hence insoluble in water. In acidic pH, amino group can
undergo protonation thus making it soluble in water. It
breaks down slowly to harmless products amino sugars,
which are completely absorbed by the human body [14].
Chitin, a structural Moreover, its ability in improving the
dissolution properties and bioavailability of poorly-soluble
drugs has been proved [14-17]. Carvedilol nonselective
β-adrenoreceptor blocker, chemically (±)-1-(Carbazol-4-
yloxy)-3-[[2-(o-methoxyphenoxy) ethyl] amino]-2-propanol,
slightly soluble in ethyl ether; and practically insoluble in
water, gastric fluid (simulated, TS, pH 1.1), and intestinal
fluid (simulated, TS without pancreatin, pH 7.5)
Compounds with aqueous solubility less than 1% w/v
often represents dissolution rate limited absorption
[18,19]. The solid systems for several drugs using chito-
san have been reported with solid dispersions, co-
ground mixtures and solid complexes, physical mixture
and co- ground products and spray dried products at
different ratios. There are reports on the improvement
of dissolution rate and bioavailability of poorly water sol-
uble drugs by precipitation of chitosan using solvent
change method [20-22]. Hence objectives of present
investigation were (i) To assess the feasibility of chitosan
and chitosan chlorhydrate in enhancing dissolution rate
of carvedilol by preparing hydrosols using solvent
change method. (ii) To compare efficacy low molecular
weight chitosan (chitosan chlorhydrate) and chitosan
in enhancement of dissolution of carvedilol. (iii) To
compare effect of different methods like solvent changeapproach, co- ground mixture and solid dispersions on
dissolution rate of carvedilol.
Methods
Materials
Carvedilol was obtained as gift sample from Lupin
Pharma. Ltd. Pune. India. Chitosan (85% deactylated),
chitosan chlorhydrate obtained from mehtani chitosan
India. Hydrochloric acid (35-38%), glacial acetic acid
(99.5%), sodium citrate (99.5%) was purchased from




The composition of different batchhes is given in Table 1.
Chitosan solution was prepared by soaking chitosan and
Table 4 Practical yield, drug content and solubility data
in water and SGF for the pure drug and prepared









Carvedilol - - 0.13 ± 0.002 0.43 ± 0.001
C1 85.62 99.23 ±0.58 0.21 ± 0.001 0.41 ± 0.004
C2 80.32 99.12 ± 0.76 0.37 ± 0.002 0.39 ± 0.004
C3 75.86 99.45 ± 0.68 0.39 ± 0.004 1.2 ± 0.002
C4 64.83 99.78 ± 0.98 0.36 ± 0.004 1.03 ± 0.002
C5 59.76 98.24 ± 1.23 0.35 ± 0.001 1.04 ± 0.004
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a weighed amount of drug was dispersed in chitosan so-
lution by stirring at 4000 rpm for 25 min. then disper-
sion was added to sodium citrate solution to precipitate
chitosan on drug to form hydrosols. The precipitate
obtained was filtered through Whatmann No. 1 filter
paper using vacuum filtration unit and dried at 45°C for
24 h. the dried product then passed through sieve No.
60 to obtain uniform size distribution. A control hydro-
sol formulation without chitosan was also prepared
(C12) (Table 1). The practical yield of prepared hydro-
sols was calculated.C6 86.86 98.45 ± 0.98 0.31 ± 0.005 1.00 ± 0.004
C7 82.23 99.14 ± 1.45 0.72 ± 0.001 0.86 ± 0.001
C8 73.32 99.56 ± 1.02 0.74 ± 0.005 0.41 ± 0.001
C9 69.46 99.89 ± 1.13 0.60 ± 0.005 0.42 ± 0.006
C10 63.23 99.25 ± 0.87 0.54 ± 0.005 0.41 ± 0.001
C11 59.21 98.78 ± 0.96 0.68 ± 0.004 0.42 ± 0.002
C12 93.32 99.63 ± 1.96 0.14 ± 0.001 0.41 ± 0.004
C13 100 98.32 ± 1.06 0.43 ± 0.002 0.42 ± 0.007
C14 100 99.32 ± 1.23 0.78 ± 0.001 0.45 ± 0.004Preparation of co-grind mixture
The composition of different batches is given in Table 2.
Listed amount of carvedilol was accurately weighed and
co grinded with chitosan and chitosan chlorhydrate in
mortar for 30 min. Product then passed through sieve
No. 60 to obtain uniform size distribution. A control
formulation without chitosan was also prepared (C24)
(Table 2).C15 100 98.65 ± 0.98 2.36 ± 0.004 0.46 ± 0.003
C16 100 99.12 ± 1.24 1.2 ± 0.001 0.55 ± 0.004
C17 100 98.56 ± 0.91 1.40 ± 0.001 0.46 ± 0.002
C18 100 99.12 ± 0.85 0.45 ± 0.002 0.41 ± 0.003
C19 100 98.95 ± 0.89 1.23 ± 0.004 0.42 ± 0.002
C20 100 99.12 ± 0.92 2.01 ± 0.004 0.50 ± 0.004
C21 100 99.17 ± 1.44 3.21 ± 0.001 0.33 ± 0.008
C22 100 98.32 ± 1.56 2.14 ± 0.006 0.40 ± 0.002
C23 100 99.32 ± 0.97 3.45 ± 0.003 0.33 ± 0.001
C24 100 99.10 ± 1.12 0.23 ± 0.002 0.43 ± 0.002Preparation of solid dispersions
The composition of different batches is given in Table 3.
Chitosan solution was prepared by soaking chitosan and
chitosan chlorhydrate in 1% glacial acetic acid for 3 hrs.
A weighed amount of drug was dispersed in chitosan so-
lution by stirring at 4000 rpm for 25 min, and then dis-
persion was dried at 45°C for 24 hrs. The dried product
then passed through sieve No. 60 to obtain uniform
size distribution. A control dispersion formulation with-












C25 500 0.05 - 20
C26 500 0.2 - 20
C27 500 0.4 - 20
C28 500 0.6 - 20
C29 500 1 - 20
C30 500 - 0.05 20
C31 500 - 0.2 20
C32 500 - 0.4 20
C33 500 - 0.6 20
C34 500 - 0.8 20
C35 500 - 1 20
C36 500 - - 20
C25 98.35 98.56 ± 0.97 0.42 ± 0.003 0.46 ± 0.004
C26 99.56 99.45 ± 1.35 0.78 ± 0.004 0.47 ± 0.001
C27 99.00 99.78 ± 1.65 1.38 ± 0.004 0.36 ± 0.002
C28 99.23 99.87 ± 0.94 1.53 ± 0.001 0.45 ± 0.002
C29 99.65 98.92 ± 0.96 0.97 ± 0.004 0.47 ± 0.004
C30 98.32 98.23 ± 0.98 0.26 ± 0.002 0.48 ± 0.005
C31 99.32 99.15 ± 0.0.91 0.54 ± 0.003 0.45 ± 0.007
C32 99.23 99.25 ± 1.25 0.65 ± 0.001 0.40 ± 0.003
C33 99.78 99.42 ± 1.32 0.68 ± 0.002 0.47 ± 0.002
C34 99.65 99.89 ± 1.20 0.89 ± 0.004 0.48 ± 0.004
C35 99.21 99.47 ± 1.02 1.62 ± 0.002 0.42 ± 0.003
C36 98.96 99.56 ± 1.05 0.13 ± 0.006 0.42 ± 0.004Solubility, drug content determination
An excess amount of carvedilol or prepared formula-
tions was placed in the vials containing 10 ml of differ-
ent solvents (water and simulated gastric fluid (SGF)
without enzymes pH 1.2) the vials were agitated in a
Figure 1 Comparative FTIR pattern of carvedilol and Chitosan based hydrosols, solid dispersions and co grinding mixture. A. chitosan,
B. Carvedilol, C.0.2% chitosan hydrosols, D. 0.4% Ch-chlorhydrate hydrosols, E. SD 0.4% chitosan, F. SD 0.8% Ch-chlorhydrate, G. 0.4% chitosan
cogrind mixture, H. 0.4% ch-chlorhydrate cogrind mixture.
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was filtered through a membrane filter (0.45 μm) the
amount of drug solublized was analyzed spectrophoto-
metrically (JASCO, V-530, Japan) at 241.5 nm. This
study was carried out to determine the saturation solu-
bility of carvedilol in water and SGF.
For determination of drug content, prepared hydro-
sols, solid dispersions and co-ground mixture (10 mg)
were triturated with SGF and finally volume was made
up to 100 ml with the same. The solution was filtered
through a membrane filter (0.45 μm) the amount of
drug solublized was analyzed spectrophotometrically
(JASCO, V-530, Japan) at 241.5 nm after sufficient dilu-
tions with SGF.
Infrared (IR) spectroscopy
IR spectroscopy was conducted using a Shimadzu FTIR
8300S Spectrophotometer (Shimadzu, Tokyo, Japan) and
the spectrum was recorded in the wavelength region of4000–400 cm−1. The procedure consisted of dispersing a
sample (drug, mixture of drug and polymer and pre-
pared hydrosols) in KBr and compressing into discs by
applying a pressure of 5 t for 5 min in a hydraulic press.
The pellet was placed in the light path and the spectrum
was recorded. All spectra were collected as an average of
three scans at a resolution of 2 cm−1.Differential scanning colorimetry (DSC)
DSC was performed using DSC-60A (Shimadzu, Tokyo,
Japan) calorimeter to study the thermal behavior of drug
alone and prepared co-hydrosols. The samples were
heated in hermetically sealed aluminum pans under ni-
trogen flow (30 ml/min) at a scanning rate of 10°C/min
from 50°C to 300°C. Empty aluminum pan was used as a
reference. The physical mixture of drug with excipients
for compatibility studies was prepared by triturating the
drug with excipients in a dried mortar for 5 min.
Figure 2 Comparative P-XRD pattern of carvedilol and Chitosan
based hydrosols, solid dispersions and co grinding mixture. A.
Carvedilol, B. 0.2% chitosan hydrosols, C. 0.4% Ch-chlorhydrate
hydrosols, D. SD 0.4% chitosan, E. SD 0.8% Ch-chlorhydrate, F. 0.4%
chitosan cogrind mixture, G. 0.4% ch-chlorhydrate cogrind mixture,
H. chitosan.
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The X-ray diffraction patterns of pure drug and the
optimized hydrosols formulation were recorded using
PHilips analytical X-ray diffractometer (Model: PW
3710) (PHilips, Almelo, The Netherlands) with a copper
target over the interval of 5–70° 2θ-1. The conditions
were: voltage 40 kV; current 30 mA; scanning speed
2∘/min; temperature of acquisition: room temperature;
detector: scintillation counter detector; sample holder:
non-rotating holder.
Electron microscopy (EM)
The surface characteristics of the pure drug and pre-
pared hydrosols were studied by binocular EM (NIKON,
Tokyo, Japan) at 100 × .
In vitro dissolution study
The dissolution rate of Carvedilol alone and prepared for-
mulations were measured in triplicate in a dissolution ap-
paratus (Lab India, Model Disso 2000 Tablet dissolution
test apparatus, Mumbai, India) using apparatus USP Type
II. Dissolution studies were carried out using 900 mL
SGF (Simulated gastric fluid pH 1.2) at 37° ± 0.5°C
at 50 rpm. 30 mg carvedilol or its equivalent amount for-
mulations were placed in 900 mL of SGF. 5 mL samples
were withdrawn after 15, 30, 45 min. Replaced each time
with 5 mL fresh SGF to maintain a proper sink condi-
tion. The solutions were immediately filtered through
0.45 μm membrane filter, diluted and the concentration
of carvedilol was determined spectro-photometrically at
241.5 nm.
Stability study
After determining the drug content, the optimized for-
mulations were charged for accelerated stability studies
as per ICH guidelines. The samples (each 100 mg, n = 3)
were kept for stability studies at 40 ± 2°C and 75 ± 5%
RH for a period of 6 months in environmental test
chamber (HMG INDIA, Mumbai). The samples were
kept in glass vials sealed with rubber plugs. 10 mg of
stored hydrosols were taken out at 15, 30, 60, 90 and
180 days, they were analyzed for drug content and phys-
ical change.
Results and discussion
The solubility, dissolution behavior and permeability of a
drug are the key determinants of its oral bioavailability.
The solubility data of Carvedilol reveals that it is poorly
soluble in water. Therefore, the improvement of carvedi-
lol dissolution from its oral solid dosage forms is of great
concern. The practical yield in case of hydrosols was
ranged from 59.76 to 92.32% (Table 4).
The practical yield was found to be decreased with the
increase in polymer concentration due to the formationof a thick viscous chitosan solution from which separ-
ation of the drug hydrosols was difficult. The drug con-
tent was found to be good and uniform among the
different batches of hydrosols, cogrind mixture and solid
dispersions ranged from 98.24 to 99.89% (Table 4). The
solubility studies of the chitosan cogrind mixture, C-15
showed highest solubility of drug in both water
(2.36 mg/ml) in comparison with pure drug (0.13 mg/
ml). If we compare solubility data of chitosan and chito-
san chlorhydrtae batch C21 showed better aqueous solu-
bility (3.21 mg/ml). No difference was observed in case
of solubility in simulated gastric fluid. The difference in
aqueous solubility of chitosan and chitosan chlorhydrate
may be due to better enhanced wetting property due to
salting out, low molecular weight of chitosan chlorhydrate.
In addition, as the concentration of chitosan or chitosan





0.2% Chitosan hydrosols Nil
0.4% Chitosan chlorhydrate hydrosols Nil
0.2% Chitosan solid dispersions Nil
0.8% Chitosan chlorhydrate solid dispersions Nil
0.4% Chitosan Co-grinding 153.78
0.4% Chitosan chlorhydrate Co-grinding 152.97
Figure 3 Comparative DSC of carvedilol and formulations A.
Carvedilol, B. 0.2% Chitosan hydrosols, C. 0.4% Chitosan chlorhydrate
hydrosols, D. 0.2% Chitosan solid dispersions, E. 0.8% Chitosan
chlorhydrate solid dispersions, F. 0.4% Chitosan Co-grinding, G. 0.4%
Chitosan chlorhydrate Co-grinding.
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gradually increased up to a certain concentration followed
by decrease in the solubility. If we compare the methods
of formulation co-grind mixture showed higher solubility
data than solid dispersions and hydrosols, this might due
to micronization or sustained supersaturation of material
in media for cogrind mixture.
The possible interaction between drug and chitosan
as hydrosol formers were studied by IR spectroscopy
(Figure 1). The pure carvedilol showed peaks at 3300–
3500 cm-1, onset around 1600 cm-1, other around
1500 cm-1, 1000–1300 cm-1 due to presence of N-H
stretch, O-H stretch, consistent with aromatic com-
pounds and C-OH stretch respectively. It was observed
that all important peaks due to functional group of drug
are present in the hydrosols along with some new in-
tense peaks indicating the presence of hydrogen bond-
ing. Also there are peaks observed in the range of
400–800 cm-1 in hydrosols prepared from chitosan
chlorhydrate indicative of halogen hydrogen interaction.
The PXRD patterns of the pure drug and the hydrosols
are shown in Figure 2. The XRD scan of carvedilol
showed intense peak of cystallanity at 22.7° (2θ) with
peak intensity of 1832 indicating its crystalline nature.The relative degree of crystllanity values of carvedilol
hydrosols at specific angle are 1.22, 1.08, 1.18, 0.833,
1.04, 1.00 for prepared chitosan and chitosan chlorhy-
drate hydrosols as shown in Figure 2 respectively. It
indicates crystalline nature of carvedilol in prepared
hydrosols.
The results of DSC studies are given in Figure 3 and
Table 5. Pure carvedilol showed a sharp endotherm at
155.94°C corresponding to its melting point. There was
no appreciable change in the melting endotherms of the
cogrind mixture as compare pure drug. However there
is disappearance of melting endothermic peaks of carve-
dilol when formulated into hydrosols and solid disper-
sions meaning is that drug has been converted into
amorphous form and chitosan and chitosan chlorhydtare
in crystalline form. The endothermic peaks for chitosan
and chitosan chlorhydrate were observed in the range of
200–225°C.
The photomicrographs of pure carvedilol and the
selected crystal formulations are given in Figure 4. The
pure carvedilol was characterized by hydrosols of bigger
size and regular shape with an apparently smooth sur-
face. In contrast hydrosols were present in the form of
fine powder. Additionally, solid dispersions were porous
and with rough surface which might have resulted
in the enhanced dissolution rate as compared to pure
drug. The size of hydrosols was comparatively less than
carvedilol.
The increase in the carvedilol solubility, although little,
and dramatically increase in its dissolution rate from pre-
pared hydrosols, cogrind mixture and solid dispersions
can be explained as follow (as shown in Figures 5 & 6):
Chitosan has been proposed as a useful excipient for
enhancing the bioavailability of poorly water-soluble
compounds [23]. Chitosan and its derivatives have been
reported as a good vehicle for enhancing the solubility
and dissolution of poorly water-soluble drugs [24-26].
Chitosan dissolves readily in most of the acid solutions
and upon dissolution, amine groups of the polymer
become protonated, resulting in a positively charged
Figure 4 Electronic microphotographs of optimized formulations.
Figure 5 In vitro release of carvedilol from the prepared hydrosol formulations in SGF. The points represent mean values, n = 3.
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Figure 6 In vitro release of carvedilol from the prepared cogrind formulations in SGF. The points represent mean values, n = 3.
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glutamate, etc.) that are soluble in water [27].
The earlier literature reveals that dissolution rate not
only depends on the surface area and particle size of the
processed powder, but is greatly affected by crystal
morphhology and wettability [27] So increased wettabil-
ity of the drug by the adsorption of chitosan and chito-
san chlorhydrate onto the hydrophobic surface of the
drug is the first reason. In a previous study also, chitosan
showed increased solubility and dissolution rate of na-
proxen due to adsorption on its surface [26]. One inter-
esting case was observed all solid dispersions showed
100% drug release within 15 minutes. Carvedilol exhib-
ited pH dependent solubility. Its solubility decreases
with increasing pH then starts decreasing after pH 4. At
lower pH values protonated form of carvedilol and its
salts generated in situ will determine its solubility.
Hydrochloride salt generated in situ in an acidic me-
dium might be less soluble in this medium than the pro-
tonated carvedilol itself. At basic pH as the pH increases
from 9.2 to 11 its solubility remains more or less con-
stant [28]. In formulation of solid dispersions glacial
acetic acid was used so acetic acid incorporates acidity
to the formulation that’s why there might be possibility
of enhancement of dissolution rate of carvediol [28].
The difference in dissolution rate enhancement by












Time 0 days 99.56 ± 1.16 98.77 ± 1.31 98.19 ± 2.13
Time 90 days 99.46 ± 1.38 98.67 ± 1.44 98.09 ± 2.34
Time 180 days 99.26 ± 1.10 98.47 ± 1.22 97.69 ± 2.01the trend found was that for the two types of chitosan
(base and salt), the lower the Mw, the faster was the
drug dissolution. This behavior was predictable taking
into account the relationship between Mw and viscosity
of polymer solution [29].
Upon contact with the acidic medium; chitosan swells
and forms a gel. The diffusion of the drug through the
gel into the release medium would be retarded by in-
creasing the viscosity of the polymer, and hence of the
gel [30]. On the other hand, the chitosan chlorhydrate
led to faster drug dissolution than chitosan. The explan-
ation to this behavior was found in the differences in the
wetting rate, solubilities and swelling capacity of the
chitosan and chitosan salts, chitosan chlorhydrate rap-
idly wet and dissolve upon its incorporation into the dis-
solution medium, whereas the CS base, less water
soluble, would take more time to dissolve. In order to
clarify the causes of significant difference in the dis-
solution rate, the surface morphology of the hydrosols
was examined by electronic microscope (EM). Thus
the fine and fluffy physical state of C-3 hydrosols
along with their porous and rough surface as sup-
ported by EM might also have contributed to the
enhanced solubility and dissolution rate of carvedilol
from these hydrosols.
The physical stability of optimized formulations was











99.66 ± 1.24 98.17 ± 1.14 99.46 ± 1.11 98.86 ± 1.15
99.76 ± 1.32 98.67 ± 1.43 99.27 ± 1.12 98.66 ± 1.34
99.16 ± 1.16 98.97 ± 1.25 99.29 ± 1.14 99.10 ± 1.17
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change in color was found. The drug content in all the
formulations was found to be within the limit. The drug
content within the formulations is shown in the Table 6.
Conclusions
The present study investigated successful and simple meth-
ods to enhance the dissolution rate of carvedilol by using
chitosan and chitosan chlorhydrate. If this process can be
scaled-up to manufacturing level, this technique has the po-
tential to develop into an invaluable technology in future.
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